We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (DD)

24 Mar 2020 08:55

RNS Number : 3481H
Redmile Group LLC
24 March 2020
 

FORM 8 (DD)

 

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)

Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

RM Special Holdings 3, LLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Redx Pharma PLC

(d) Status of person making the disclosure:

e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)

Offeror

(e) Date dealing undertaken:

23/03/2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

If YES, specify which:

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing

 

Class of relevant security:

 

Ordinary shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

91,676,346

48.25

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

91,676,346

48.25

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

(i) Party to an offer or person acting in concert (except for a principal trader in the same group as a connected adviser)

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary shares

Purchase

 

127,450

£0.155

Ordinary shares

Purchase

 

3,050,000

£0.155

 

(ii) Principal trader where the sole reason for the connection is that the principal trader is in the same group as a connected adviser

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

23/03/2020

Contact name:

Rachel Chang

Telephone number:

+1 415 489 9980

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DCCEAPDLASFEEEA
Date   Source Headline
27th Oct 20227:00 amRNSRedx to Present Poster at ASN Kidney Week
11th Oct 20227:00 amRNSFirst Patient Dosed in Phase 2a Trial for RXC007
3rd Oct 20227:00 amRNSRedx Presents RXC007 Preclinical and Phase 1 Data
29th Sep 20227:41 amRNSRedx to Present Poster on RXC007 at ICLAF
6th Sep 20227:00 amRNSTR-1: Notification of major holdings
31st Aug 20227:00 amRNSRedx to Present at the ERS International Congress
5th Aug 202211:52 amRNSCompletion of Placing and Director/PDMR Dealings
3rd Aug 20221:43 pmRNSProposed Secondary Placing of Shares via ABB
26th Jul 20221:47 pmRNSExercise of Options, PDMR Dealing and TVR
11th Jul 20227:00 amRNSRedx to Present at Virtual Investor Forum
27th Jun 20227:00 amRNSEncouraging Data on Porcupine and ROCK Inhibitors
23rd Jun 20227:00 amRNSInterim Results for the Six Months Ended 31 March
20th Jun 20227:00 amRNSRedx to Present at the ECM Congress
16th Jun 20227:00 amRNSNotice of Interim Results
15th Jun 20227:00 amRNSPan-RAF Inhibitor to Enter Clinical Development
9th Jun 20224:34 pmRNSTR-1: Notification of major holdings
8th Jun 20221:28 pmRNSTR-1: Notification of major holdings
7th Jun 20228:11 amRNSAdmission of Placing Shares
6th Jun 202211:56 amRNSResults of General Meeting
30th May 20227:00 amRNSRedx Presents Poster on RXC004 at ASCO
25th May 20227:00 amRNSRedx to Present at Jefferies Healthcare Conference
20th May 20227:00 amRNSNew Grant of Options
19th May 20222:34 pmRNSNew Grant of Options
19th May 202212:14 pmRNSResult of Accelerated Bookbuild
18th May 20226:28 pmRNSLaunch of Placing via Accelerated Bookbuild
27th Apr 20223:00 pmRNSRedx to Present at ASCO
8th Apr 20226:00 pmRNSRedx Presents Encouraging RXC004 Preclinical Data
5th Apr 20227:00 amRNSCollaboration with the Garvan Institute
30th Mar 20227:00 amRNSNomination of Clinical Development Candidate
24th Mar 20227:00 amRNSRedx to Present at the AACR Annual Meeting
10th Mar 20227:00 amRNSRedx Presents Encouraging Phase 1 Data for RXC007
9th Mar 20227:00 amRNSBoard Committee Changes
8th Mar 202212:30 pmRNSResult of AGM
2nd Mar 20227:00 amRNSRedx to Present at Cowen Health Care Conference
28th Feb 20227:00 amRNSRedx to Present at ILD Summit 2022
11th Feb 20224:43 pmRNSNotice of AGM
28th Jan 20227:00 amRNSNew Grant of Share Options
27th Jan 20227:01 amRNSAppointment of Non-Executive Director
27th Jan 20227:00 amRNSFinal Audited Results and Operational Update
25th Jan 202212:00 pmRNSNotice of Preliminary Results
23rd Dec 20217:00 amRNSRedx to Receive Milestone Payment of $9m from AZ
9th Dec 20214:41 pmRNSSecond Price Monitoring Extn
9th Dec 20214:36 pmRNSPrice Monitoring Extension
9th Dec 20212:06 pmRNSSecond Price Monitoring Extn
9th Dec 20212:00 pmRNSPrice Monitoring Extension
9th Dec 20217:00 amRNSRedx to receive milestone of $10m from Jazz
6th Dec 20217:00 amRNSRedx and Caris Life Sciences Announce Partnership
30th Nov 20217:00 amRNSRedx to Participate at Piper Sandler Conference
17th Nov 20217:00 amRNSRedx to Present at Jefferies London Conference
15th Nov 20217:00 amRNSFirst Patient Dosed in Phase 2 Trial of RXC004

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.